BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38063204)

  • 1. The dual HDAC and PI3K inhibitor, CUDC‑907, inhibits tumor growth and stem‑like properties by suppressing PTX3 in neuroblastoma.
    Li M; Hu Y; Wang J; Xu Y; Hong Y; Zhang L; Luo Q; Zhen Z; Lu S; Huang J; Zhu J; Zhang Y; Que Y; Sun F
    Int J Oncol; 2024 Feb; 64(2):. PubMed ID: 38063204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CUDC907, a dual phosphoinositide-3 kinase/histone deacetylase inhibitor, promotes apoptosis of NF2 Schwannoma cells.
    Huegel J; Dinh CT; Martinelli M; Bracho O; Rosario R; Hardin H; Estivill M; Griswold A; Gultekin S; Liu XZ; Fernandez-Valle C
    Oncotarget; 2022; 13():890-904. PubMed ID: 35875610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CUDC‑907 reverses pathological phenotype of keloid fibroblasts in vitro and in vivo via dual inhibition of PI3K/Akt/mTOR signaling and HDAC2.
    Tu T; Huang J; Lin M; Gao Z; Wu X; Zhang W; Zhou G; Wang W; Liu W
    Int J Mol Med; 2019 Nov; 44(5):1789-1800. PubMed ID: 31545402
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Valproic acid shows a potent antitumor effect with alteration of DNA methylation in neuroblastoma.
    Gu S; Tian Y; Chlenski A; Salwen HR; Lu Z; Raj JU; Yang Q
    Anticancer Drugs; 2012 Nov; 23(10):1054-66. PubMed ID: 22863973
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synergistic efficacy of inhibiting MYCN and mTOR signaling against neuroblastoma.
    Kling MJ; Griggs CN; McIntyre EM; Alexander G; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
    BMC Cancer; 2021 Sep; 21(1):1061. PubMed ID: 34565342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells.
    Condorelli F; Gnemmi I; Vallario A; Genazzani AA; Canonico PL
    Br J Pharmacol; 2008 Feb; 153(4):657-68. PubMed ID: 18059320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Type-specific roles of histone deacetylase (HDAC) overexpression in ovarian carcinoma: HDAC1 enhances cell proliferation and HDAC3 stimulates cell migration with downregulation of E-cadherin.
    Hayashi A; Horiuchi A; Kikuchi N; Hayashi T; Fuseya C; Suzuki A; Konishi I; Shiozawa T
    Int J Cancer; 2010 Sep; 127(6):1332-46. PubMed ID: 20049841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PI3K Inhibitor Combined With Chemotherapy Can Enhance the Apoptosis of Neuroblastoma Cells In Vitro and In Vivo.
    Geng X; Xie L; Xing H
    Technol Cancer Res Treat; 2016 Oct; 15(5):716-22. PubMed ID: 26224681
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.
    Lu J; Guan S; Zhao Y; Yu Y; Woodfield SE; Zhang H; Yang KL; Bieerkehazhi S; Qi L; Li X; Gu J; Xu X; Jin J; Muscal JA; Yang T; Xu GT; Yang J
    Cancer Lett; 2017 Aug; 400():61-68. PubMed ID: 28455243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of PI3K and FGFR inhibitors alone and in combination, and with/without cytostatics in childhood neuroblastoma cell lines.
    Holzhauser S; Lukoseviciute M; Papachristofi C; Vasilopoulou C; Herold N; Wickström M; Kostopoulou ON; Dalianis T
    Int J Oncol; 2021 Feb; 58(2):211-225. PubMed ID: 33491755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CUDC‑907 suppresses epithelial‑mesenchymal transition, migration and invasion in a 3D spheroid model of bladder cancer.
    Ho JN; Jeon JS; Kim DH; Ryu H; Lee S
    Oncol Rep; 2023 Jun; 49(6):. PubMed ID: 37165925
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone deacetylase HDAC2 regulates microRNA-125a expression in neuroblastoma.
    Liu D; Tang X; Huang Z; Wen J; Zhou Y
    Brain Behav; 2022 Feb; 12(2):e2401. PubMed ID: 35060363
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Jin Q; Chen Y; Du S; Xu D; Yue J; Cai L; Yuan X
    Curr Cancer Drug Targets; 2022; 22(11):919-930. PubMed ID: 35909289
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual Targeting of PI3K and HDAC by CUDC-907 Inhibits Pediatric Neuroblastoma Growth.
    Chilamakuri R; Agarwal S
    Cancers (Basel); 2022 Feb; 14(4):. PubMed ID: 35205815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p21Waf1/Cip1 is a common target induced by short-chain fatty acid HDAC inhibitors (valproic acid, tributyrin and sodium butyrate) in neuroblastoma cells.
    Rocchi P; Tonelli R; Camerin C; Purgato S; Fronza R; Bianucci F; Guerra F; Pession A; Ferreri AM
    Oncol Rep; 2005 Jun; 13(6):1139-44. PubMed ID: 15870934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Romidepsin (FK228) and its analogs directly inhibit phosphatidylinositol 3-kinase activity and potently induce apoptosis as histone deacetylase/phosphatidylinositol 3-kinase dual inhibitors.
    Saijo K; Katoh T; Shimodaira H; Oda A; Takahashi O; Ishioka C
    Cancer Sci; 2012 Nov; 103(11):1994-2001. PubMed ID: 22924958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LncRNA NORAD accelerates the progression and doxorubicin resistance of neuroblastoma through up-regulating HDAC8 via sponging miR-144-3p.
    Wang B; Xu L; Zhang J; Cheng X; Xu Q; Wang J; Mao F
    Biomed Pharmacother; 2020 Sep; 129():110268. PubMed ID: 32563146
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioevaluation of a dual PI3K/HDAC inhibitor for the treatment of diffuse large B-cell lymphoma.
    Zhang K; Huang L; Lai F; Lin S; Tian H; Wu D; Chen X; Xu H
    Bioorg Med Chem Lett; 2022 Sep; 71():128825. PubMed ID: 35644299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FoxM1 Regulates Proliferation and Apoptosis of Human Neuroblastoma Cell through PI3K/AKT Pathway.
    Liao J; Jiang L; Wang C; Zhao D; He W; Zhou K; Liang Y
    Fetal Pediatr Pathol; 2022 Jun; 41(3):355-370. PubMed ID: 32901528
    [No Abstract]   [Full Text] [Related]  

  • 20. GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3.
    Fabian J; Lodrini M; Oehme I; Schier MC; Thole TM; Hielscher T; Kopp-Schneider A; Opitz L; Capper D; von Deimling A; Wiegand I; Milde T; Mahlknecht U; Westermann F; Popanda O; Roels F; Hero B; Berthold F; Fischer M; Kulozik AE; Witt O; Deubzer HE
    Cancer Res; 2014 May; 74(9):2604-16. PubMed ID: 24419085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.